SCHEMBL648219

SCHEMBL648219

NOC(=O)CC[C@H](N)C(=O)ON

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 2/20 0.38
GRM8 O00222 1/20 0.38
GRM6 O15303 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GSR P00390 1/20 0.38
CYP1A2 P05177 1/20 0.38
GRIK1 P39086 1/20 0.38
GRM5 P41594 1/20 0.38
GRIA1 P42261 1/20 0.38
GRIA2 P42262 1/20 0.38
GRIA3 P42263 1/20 0.38
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
GRIA4 P48058 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIK2 Q13002 1/20 0.38
GRIK3 Q13003 1/20 0.38
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3510151 1.00 SLC1A1 (0.38) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL1373976 1.00 SLC1A1 (0.38) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL21002223 0.87 GSR (0.33) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL2723398 0.85 SLC1A1 (0.51) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL29831114 0.82 GRM8 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL22502695 0.82 GRM8 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL5496875 0.82 GRM8 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL167845 0.82 ALOX15 (0.58) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL8697 0.82 SLC1A1 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL17724321 0.82 SLC1A1 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118976052-A Preparation method and application of polyphenol extract of fresh flavedo of flavedo 江苏海洋大学 2024-11-19 CN claimed
CN-118874229-A Separation membrane for delaying physical aging and preparation method and application thereof 天津大学 2024-11-01 CN claimed
CN-118638826-A Application of surfactant or nano-disc in synthesizing membrane protein in cell-free synthesis system 清华大学 2024-09-13 CN claimed
CN-118638764-A Method for producing ACE2 using cell-free protein expression system and use of ACE2 清华大学 2024-09-13 CN claimed
CN-118165851-A Additives for cell-free reaction systems, compositions and uses thereof 清华大学 2024-06-11 CN claimed
CN-117942408-A Inorganic nano-enzyme for catalyzing glutamic acid to convert ammonia, preparation method and application thereof in bone cancer pain treatment medicine 复旦大学 2024-04-30 CN claimed
CN-117732092-A High-efficiency low-energy-consumption amino acid evaporative crystallization equipment and process 山东祥瑞药业有限公司 2024-03-22 CN claimed
CN-115531335-B Oselta phosphate Wei Kou disintegrating tablet and preparation method thereof 合肥医工医药股份有限公司 2024-01-30 CN claimed
CN-117310064-A Method for detecting 21 free amino acids in tea leaves 西北农林科技大学 2023-12-29 CN claimed
US-20230417668-A1 SURFACE PLASMON RESONANCE SIGNAL AMPLIFICATION SWK FUNDING LLC 2023-12-28 US claimed
US-20060058221-A1 Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders MILLER LANDON C 2006-03-16 US claimed
US-20050054580-A1 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells NOVELOS THERAPEUTICS, INC. (US) 2005-03-10 US claimed
EP-1131340-B1 HEXAPEPTIDE WITH THE STABILIZED DISULFIDE BOND AND DERIVATIVES THEREOF REGULATING METABOLISM, PROLIFERATION, DIFFERENTIATION AND APOPTOSIS NOVELOS THERAPEUTICS INC (US) 2004-10-13 EP claimed
US-20030077334-A1 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanism for normal and transformed cells KOZHEMYAKIN LEONID A (RU) 2003-04-24 US claimed
CN-1371388-A Hexapeptide with stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation differentiation and apoptosis NOVILOSE MEDICAL CO (US) 2002-09-25 CN claimed
US-20020016288-A1 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells KOZHEMYAKIN LEONID A (RU) 2002-02-07 US claimed
US-6312734-B1 FORMING AN OXIDIZED GLUTATIONE COMPLEX WITH PLATINUM OR PALLADIUM NOVELOS THERAPEUTICS, INC. 2001-11-06 US claimed
EP-1131340-A2 HEXAPEPTIDE WITH THE STABILIZED DISULFIDE BOND AND DERIVATIVES THEREOF REGULATING METABOLISM, PROLIFERATION, DIFFERENTIATION AND APOPTOSIS Novelos Therapeutics, Inc. (US) 2001-09-12 EP claimed
WO-2000031120-A2 HEXAPEPTIDE WITH THE STABILIZED DISULFIDE BOND AND DERIVATIVES THEREOF REGULATING METABOLISM, PROLIFERATION, DIFFERENTIATION AND APOPTOSIS NOVELOS THERAPEUTICS, INC. (US) 2000-06-02 WO claimed
CN-1041159-A Peptide compounds HAFSLUND NYCOMED BIOREG (NO) 1990-04-11 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016288-A1 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells GPX4, GPX1, GSR SLC1A1 1120/4885GRM8 803/4885GRM6 388/4885
US-20030077334-A1 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanism for normal and transformed cells GPX4, GPX1, GSR SLC1A1 1119/4885GRM8 807/4885GRM6 392/4885
US-20050054580-A1 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells GPX4, GPX1, GSR SLC1A1 1120/4885GRM8 803/4885GRM6 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.